2008

Perlegen Sciences Out-Licenses Intellectual Property for Genetic Diagnostic. [ PDF }
July 15, 2008.

Perlegen Gains Exclusive Access to Data on Four Million Patients to Enable Personalized Medicine. [ PDF ]
March 18, 2008

Perlegen and SC Liver Research Consortium to Collaborate on Interferon Response in Hepatitis C Patients. [ PDF ]
February 19, 2008

Perlegen Fills Out Leadership Team to Prepare for Multiple Personalized Medicine Programs. [PDF]
February 14, 2008

2007

Perlegen Expands Leadership Team to Prepare for Landmark Personalized Medicine Programs. [PDF]
October 31, 2007

Perlegen’s Contribution to Phase 2 Hapmap of Human Genetic Variation Empowers Scientists Studying Common Diseases. [PDF]
October 17, 2007

Breast Cancer Diagnostic Markers Licensed by Perlegen in Agreement with University of Cambridge and Cancer Research Technology. [PDF]
October 16, 2007

Perlegen and 454 to Collaborate in Drug Response Sequencing Study. [PDF]
October 2, 2007

Perlegen Seeking Genes Responsible for Actos® and Avandia® Side-Effects; Completed Collection of 3,000 DNA Samples. [PDF]
June 15, 2007

Perlegen Expands Senior Leadership Team with Appointment
of Bryan Walser, MD, JD. [PDF]
May 1, 2007

2006

Uncovering Genetic Diversity of Rice Varieties Could Improve Nutritional Value, Productivity of World’s Greatest Food Source. [PDF]
May 10, 2006

Perlegen Sciences, Inc. Files Registration Statement
for Proposed Initial Public Offering. [PDF]
April 7, 2006

Genetic Association Information Network Launched. [PDF]
February 8, 2006

Perlegen Forms Collaboration with Genentech in Cancer Genetics. [PDF]
January 6, 2006

2005

Pfizer and Perlegen Form New Genetics Research Collaboration to Analyze Patient DNA Samples. [PDF]
December 28, 2005.

Pfizer Invests $50 Million in Perlegen Sciences. [PDF]
December 27, 2005.

Perlegen Sciences and International Rice Research Institute to Collaborate on Rice DNA Variation Study. [PDF]
November 16, 2005

Kyushu University and Perlegen Sciences Identify Haplotypes in the Japanese Population. [PDF]
October 26, 2005

International Consortium Completes Map of Human Genetic Variation. [PDF]
October 26, 2005

Wellcome Trust Case Control Consortium Partners with Perlegen and Affymetrix to Search for Genetic Origins of Ten Complex Diseases. [PDF]
October 5, 2005

Perlegen and Merck to Work on High-density, Whole-genome Analysis Linking Genetic Variation to Molecular and Clinical Profiling. [PDF]
October 4, 2005

Research Study Provides First Whole Genome Map of Genetic Variability in Parkinson’s Disease. [PDF]
September 12, 2005

Perlegen and GlaxoSmithkline Sign New Agreement for Genetic Studies. [PDF]
August 31, 2005

RIKEN and Perlegen Begin Collaboration to Conduct High-Resolution,
Whole Genome Studies of up to 47 Common Diseases. [PDF]
July 21, 2005

Perlegen Sciences and the Pritzker Neuropsychiatric Disorders Research Consortium to Collaborate on Bipolar Disorder Study. [PDF]
July 14, 2005

Perlegen Sciences to Analyze Genetics of Common Diseases in Postmenopausal Women. [PDF]
June 30, 2005

Perlegen Sciences Announces the Establishment of Newly Formed Perlegen Sciences Japan K.K. [PDF] • 日本語
April 21, 2005

Perlegen Sciences Licenses Late-Stage Compound from Mitsubishi Pharma. [PDF] • 日本語
April 12, 2005

Perlegen Sciences to Analyze Plague-Causing Bacteria with Biodefense Grant from National Institute of Allergy and Infectious Diseases. [PDF]
April 4, 2005

Perlegen to Analyze Genetics of Rheumatoid Arthritis. [PDF]
March 10, 2005

Perlegen Raises $74 Million to Apply Pharmacogenomics to Late-Stage Drug Pipeline. [PDF]
February 28, 2005

Perlegen and Johns Hopkins Awarded Grant for Comprehensive Mutational Analysis of the Cancer Genome. [PDF]
February 23, 2005

The University of Cambridge, Cancer Research Technology, Cancer Research UK, and Perlegen Sciences Collaborate to Analyze Thousands of DNA Samples from Breast Cancer Patients. [PDF]
February 16, 2005

Worldwide Public-Private Support Enables Perlegen Sciences to Expand its Contribution to International Hapmap Project, Providing Over One Billion Genotypes in 2005. [PDF]
February 7, 2005

Perlegen Signs New Agreement with AstraZeneca. [PDF]
January 24, 2005

Perlegen Sciences to Collaborate on Pharmacogenomics Study with Johnson & Johnson Pharmaceutical Research & Development. [PDF]
January 11, 2005

2004

NIDA Joins Forces With Perlegen To Research Nicotine Addiction. [PDF]
November 17, 2004

Phyllis Whiteley Joins Perlegen Sciences As Senior Vice President, Business Development And Licensing. [PDF]
October 28, 2004

Perlegen Sciences Awarded Contract to Identify Genetic Variation in Laboratory Mouse Strains by the National Institute of Environmental Health Sciences. [PDF]
Mouse SNP Discovery Website [mouse.perlegen.com]
October 26, 2004

Perlegen and GlaxoSmithKline Sign Agreement for Additional Collaboration. [PDF]
October 12, 2004

Perlegen Sciences, Max Planck Institute for Developmental Biology, and Salk Institute for Biological Studies to collaborate on Arabidopsis DNA Variation Study. [PDF]
October 5, 2004

Perlegen Sciences to perform over 600 million genotypes in one year or less for the International Hapmap Project. [PDF]
September 30, 2004

Perlegen Sciences awarded grant to conduct whole genome study of Alzheimer's Disease by the National Institute on Aging. [PDF]
September 13, 2004

Perlegen to seek genetic basis of Autism with grant from National Institute of Mental Health. [PDF]
August 19, 2004

Perlegen Sciences and Mayo Clinic to Collaborate on Whole Genome Study of Parkinson’s Disease, Funded by the Michael J. Fox Foundation. [PDF]
June 14, 2004

Perlegen Sciences appoints Russell Singleton as Vice President, Engineering, and Informatics. [PDF]
June 8, 2004

Perlegen Sciences appoints William Sims as Chief Financial Officer. [PDF]
June 7, 2004

Perlegen Sciences Named to Red Herring’s List of the Technology Industry’s Top 100 Companies. [PDF]
May 25, 2004

Perlegen Sciences adds renowned atherosclerosis expert to scientific advisory board. [PDF]
April 28, 2004

Perlegen Sciences adds world renowned cardiovascular expert to its scientific advisory board. [PDF]
February 19, 2004

Perlegen Sciences and Galileo Genomics form collaboration to determine the genetic basis of 21 common diseases. [PDF]
January 26, 2004

Perlegen Sciences establishes genetics research collaboration with AstraZeneca. [PDF]
January 9, 2004

Perlegen Sciences teams with Pfizer to focus on drugs for major depression. [PDF]
January 8, 2004

Perlegen Sciences teams with Pfizer on metabolic syndrome research. [PDF]
January 7, 2004

2003

Perlegen Sciences expands pharmacogenomics research collaboration with Lilly. [PDF]
September 23, 2003

Perlegen Sciences awarded Biodefense Research Grant for Salmonella Studies. [PDF]
September 16, 2003

Perlegen Sciences appoints Mark McCamish to head Clinical Development Unit. [PDF]
August 19, 2003

Perlegen Sciences wins Bio-IT World 2003 Best Practices Award. [PDF]
June 25, 2003

Perlegen Scientists publish surprising discovery about the genetic basis for differences between humans and other primates. [PDF]
March 3, 2003

Perlegen to use genetic research to create new consumer products for Unilever. [PDF]
February 20, 2003

Perlegen Sciences raises $30 million in second financing round. [PDF]
January 27, 2003

Renowned nutrition and genomics expert joins Perlegen Sciences scientific advisory board. [PDF]
January 8, 2003

2002

Perlegen Sciences announces whole genome pharmacogenomics collaboration with Bristol Myers Squibb. [PDF]
December 19, 2002

Perlegen Sciences enters into pharmacogenomics research collaboration with Lilly. [PDF]
December 18, 2002

Perlegen Sciences and international team of geneticists to study type 2 diabetes. [PDF]
October 28, 2002

Paul Cusenza joins Perlegen as Vice President of Alliance Management. [PDF]
September 30, 2002

Perlegen Sciences announces collaboration with GlaxoSmithKline on whole genome pharmacogenetics study. [PDF]
September 18, 2002

Perlegen Sciences develops massively parallel genotyping platform. [PDF]
September 12, 2002

Perlegen appoints Matthew Fust as Chief Financial Officer. [PDF]
June 27, 2002

Philip N. Sussman joins Perlegen Sciences as VP of Business Development. [PDF]
March 18, 2002

2001 – 2000

DNA chip-based comparisons of conserved sequences rapidly identifies potential functional elements. [PDF]
October 5, 2001

Pixar executive joins Perlegen Sciences. [PDF]
April 18, 2001

Perlegen completes $100 Million financing. [PDF]
April 2, 2001

Affymetrix announces formation of new genomics company: Perlegen Sciences. [PDF]
October 3, 2000